Association between Serum Cortisol and DHEA-S Levels and Response to Antipsychotic Treatment in Schizophrenia
DOI:
https://doi.org/10.3889/oamjms.2015.018Keywords:
schizophrenia, cortisol, DHEA-S, responders, nonrespondersAbstract
BACKGROUND: Previous studies suggested that alterations in serum cortisol and DHEA-S levels may play a role in the pathophysiology of schizophrenia.
AIM: To compare serum cortisol and DHEA-S levels between patients with schizophrenia and healthy controls and to evaluate their association with the response to antipsychotic treatment.
MATERIAL AND METHODS: In this clinical prospective study were included 60 patients with schizophrenia and 40 healthy age and sex matched control subjects. Clinical evaluation of patients was performed using the Positive and Negative Symptom Scale. A questionnaire for socio-demographic and clinical data collection was used. For the purposes of the study, the examined group was divided in two subgroups: responders and nonresponders. Serum cortisol and DHEA-S levels were measured at baseline in all participants and after 3 and 6 weeks of the antipsychotic treatment in patients with schizophrenia.
RESULTS: Patients with schizophrenia had significantly higher serum cortisol and DHEA-S levels in comparison to the control group. Responders had significantly higher serum cortisol and DHEA-S levels compared with nonresponders.
CONCLUSION: Elevated serum cortisol and DHEA-S levels may play a role in the pathophysiology of schizophrenia and they may be related to positive response to antipsychotic treatment in patients with schizophrenia.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Kaneko M, Yokoyama F, Hoshino Y et al. Hypothalamicpituitary-adrenal axis function in chronic schizophrenia: association with clinical features. Neuropsychobiology. 1992; 25: 1–7. DOI: https://doi.org/10.1159/000118800
Yıldırım O, Dogan O, Semiz M, Kilicli F. Serum cortisol and dehydroepiandrosterone-sulfate levels in schizophrenic patients and their first-degree relatives. Psychiatry Clin Neurosci. 2011; 65: 584–91. DOI: https://doi.org/10.1111/j.1440-1819.2011.02252.x
Ryan MC, Sharifi N, Condren R, Thakore JH. Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology 2004; 29: 1065-70. DOI: https://doi.org/10.1016/j.psyneuen.2003.08.011
Walder DJ, Walker EF, Lewine RJ. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol Psychiatry. 2000; 48: 1121–32. DOI: https://doi.org/10.1016/S0006-3223(00)01052-0
Gallagher P, Watson S, Smith MS, Young AH, Ferrier IN. Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder. Schizophr Res. 2007; 90(1-3): 258-65. DOI: https://doi.org/10.1016/j.schres.2006.11.020
Zhang XY, Zhou DF, Cao LY, Wu GY, Shen YC. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology. 2005; 30(8): 1532-8. DOI: https://doi.org/10.1038/sj.npp.1300756
Yilmaz N, Herken H, Cicek HK et al. Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. Med Princ Pract. 2007; 16(2): 137-41. DOI: https://doi.org/10.1159/000098367
Hori H, Teraishi T, Sasayama D et al. Elevated cortisol level and cortisol/DHEAS ratio in schizophrenia as revealed by low-dose dexamethasone suppression test. The Open Neuropsychopharmacology. 2012; 5: 18-24. DOI: https://doi.org/10.2174/1876523801205010018
Venkatasubramanian G, Chittiprol S, Neelakantachar N, Shetty T, Gangadhar BN. Effect of antipsychotic treatment on Insulin-like Growth Factor-1 and cortisol in schizophrenia: a longitudinal study. Schizophr Res. 2010; 119(1-3): 131-7. DOI: https://doi.org/10.1016/j.schres.2010.01.033
Steen NE, Methlie P, Lorentzen S et al. Increased systemic cortisol metabolism in patients with schizophrenia and bipolar disorder: a mechanism for increased stress vulnerability? J Clin Psychiatry. 2011; 72(11): 1515-21. DOI: https://doi.org/10.4088/JCP.10m06068yel
Ritsner M, Maayan R, Gibel A et al. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur Neuropsychopharmacol. 2004; 14: 267–73. DOI: https://doi.org/10.1016/j.euroneuro.2003.09.003
Taherianfard M, Shariaty M. Evaluation of serum steroid hormones in schizophrenic patients. Indian J Med Sci. 2004; 58(1): 3-9.
Morfin R. DHEA and the brain. Taylor and Francis: London and New York, 2002. DOI: https://doi.org/10.1201/b12558
Baulieu EE, Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. J Endocrinol. 1996; 150: S221–S239.
Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology. 2003; 28: 139–68. DOI: https://doi.org/10.1016/S0306-4530(02)00064-1
Ritsner M. Pregnenolone, Dehydroepiandrosterone, and Schizophrenia: Alterations and Clinical Trials. CNS Neurosci Ther. 2010; 16:32–44. DOI: https://doi.org/10.1111/j.1755-5949.2009.00118.x
Oades RD, Schepker R. Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinology. 1994; 19(4): 373-85. DOI: https://doi.org/10.1016/0306-4530(94)90017-5
Strous RD, Maayan R, Lapidus R et al. Increased circulatory dehydroepiandrosterone and dehydroepiandrosteronesulphate in first episode schizophrenia: relationship to gender, aggression and symptomatology. Schizophr Res. 2004; 71: 427– 34. DOI: https://doi.org/10.1016/j.schres.2004.03.005
Shirayama Y, Hashimoto K, Suzuki Y, Higuchi T. Correlation of plasma neurosteroids to the severity of negative symptoms in male patients with schizophrenia. Schizophrenia Res. 2002; 58: 69–74. DOI: https://doi.org/10.1016/S0920-9964(01)00367-X
Ritsner M, Gibel A, Ram E et al. Alterations in DHEA metabolism in schizophrenia: Two-month case-control study. Eur Neuropsychopharmacol. 2006; 16: 137-46. DOI: https://doi.org/10.1016/j.euroneuro.2005.07.007
Ritsner M, Gibel A, Maayan R et al. Cortisol/Dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia. Neuropsychopharmacology. 2005; 30: 1913–22. DOI: https://doi.org/10.1038/sj.npp.1300747
Beyazyüz M, Albayrak Y, Beyazyüz E, Ünsal C, Göka E. Increased serum dehydroepiandrosterone sulfate in the first episode but not in subsequent episodes in male patients with schizophrenia. Neuropsychiatr Dis Treat. 2014; 10:687–93. DOI: https://doi.org/10.2147/NDT.S61406
di Michele F, Caltagirone C, Bonaviri G, Romeo E, Spalletta G. Plasma dehydroepiandrosterone levels are strongly increased in schizophrenia. J Psychiatr Res. 2005; 39: 267-73. DOI: https://doi.org/10.1016/j.jpsychires.2004.08.005
Garner B, Phassuliotis C, Phillips LJ et al. Cortisol and dehydroepiandrosterone-sulphate levels correlate with symptom severity in first-episode psychosis. J Psychiatr Res. 2011; 45(2): 249-55. DOI: https://doi.org/10.1016/j.jpsychires.2010.06.008
Marx CE, Stevens RD, Shampine LJ et al. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology. 2006; 31: 1249-63. DOI: https://doi.org/10.1038/sj.npp.1300952
Shulman Y, Tibbo P. Neuroactive steroids in schizophrenia. Can J Psychiatry. 2005; 50:695-702. DOI: https://doi.org/10.1177/070674370505001109
Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13: 261–7. DOI: https://doi.org/10.1093/schbul/13.2.261
Kaneda Y, Fujii A, Ohmori T. The hypothalamic-pituitaryadrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. Prog. Neuropsychopharmacol Biol Psychiatry. 2002; 26: 935–8. DOI: https://doi.org/10.1016/S0278-5846(02)00208-7
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
